Clinical Trial: Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809802) titled 'Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment' on Sept. 03.

Brief Summary: This is a single-center, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the safety and pharmacokinetic (PK) profile of vorolanib tablets in participants with hepatic impairment. A total of 24 participants (male and female) will be enrolled. Three study groups will be established, comprising participants with mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), and normal hepatic function, respectively. All participants will receive a single oral dose...